Skip to main content
. 2022 Jan 26;14(3):625. doi: 10.3390/cancers14030625

Table 10.

Retrospective clinical trial studies using CT in combination with HT.

Author(s) Cancer Site, n CT Drug(s)
(mg/m2) ×
Cycles		 Temperature
Metrics (°C)		 HT
Session		 ttreat
(min)		 Thermal
Dose		 tint
(min)		 Sequence Clinical Outcome
(Comment)
Yang et al. [140] Advanced non-small cell lung
cancer, n = 48		 1000
gemcitabine
twice weekly
× 6
75 cisplatin
twice weekly
× 6		 n.r. Ntotal:
8
Nweek:
2		 40–60 n.r. n.r. HT after CT
or
HT before CT

  • No CR 1 reported, PR 2: 37.5% (18/23), SD 3: 33.3% (16/23), PD 4: 29.2% (14/23).

  • ORR 5: 37.5% and DCR 6: 70.8%.

  • 1-and 2-year survival rates: 14% and 1.3%, respectively.

  • Toxicity, grade III: 14 patients and grade IV: no patients.

(correlation of thermometric parameters with clinical outcome not presented)
Tschoep-Lechner et al. [141] Advanced pancreatic cancer,
n = 23		 1000
gemcitabine
once weekly
× 8
25 cisplatin
twice weekly
× 8		 Tmax †: 42.1
(40.9–44.1)		 Nweek:
2
Ntotal ‡:
8		 60 n.r. 0 simultaneously

  • PR: 4.34% (1/23), SD: 30.4% (7/23), PD: 34.7% (8/23);

  • OS 7‡: 12.9 months (CI: 9.9–15.9 months).

  • Mild (grade 1 and 2) position-related pain during HT treatment.

(correlation of thermometric parameters with clinical outcome not presented)
Stahl et al. [137] Soft tissue
sarcomas, n = 46		 250 etoposide
× 4
6000
ifosfamide
× 4
50 adriamycin
× 4		 T90 †:
39.90 ± 0.74
(good
responders)
and
T90 †:
39.42 ± 1.78
(bad
responders)		 Nweek:
2
Ntotal ‡:
8		 60 CEM43°CT90†: 17.96 ± 7.16
(good responders)
CEM43°CT90†: 11.07 ± 5.58
(good responders)		 0 simultaneously

  • PR: 31.6% (6/19 in the good responder group for RECIST 8) to 37% (10/27 in the poor responder group for RECIST).

  • SD: 63.2% (12/19 for the good responder group in WHO 9 and volume) to 70.3% (19/27 in the poor responder group for volume).

  • T90 and CEM43°CT90 parameters did not differ significantly between the groups.

n: number of patients assigned to be treated with HT in combination withCT; †: mean value (±standard deviation) or mean value (range); ‡: median (range); 1 CR: complete response; 2 PR: partial response; 3 SD: stable disease; 4 PD: progression disease; 5 ORR: objective response rate; 6 DCR: disease control rate; 7 OS: overall survival; 8 RECIST: Response Evaluation Criteria in Solid Tumors; 9 WHO: world health organization.